The Latest

  • An illustrated image of clinical development for a BioPharma Dive 2021 outlook story
    Image attribution tooltip
    Kendall Davis/BioPharma Dive
    Image attribution tooltip
    Tracker

    10 clinical trials to watch in the second half of 2026

    The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

  • a photo of Epicrispr Biotechnologies CEO Amber Salzman standing in a white lab coat facing the camera with a woman behind her to her left in a white lab coat with black glasses holding a tube and syringe, and a woman in a white labcoat behind to the right facing the right touching lab tools.
    Image attribution tooltip
    Permission granted by Epicrispr Biotechnologies
    Image attribution tooltip
    Emerging biotech

    Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease

    The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral muscular dystrophy, a disease targeted by many other drugmakers.

  • A sign for Jazz Pharmaceuticals is displayed at the ASCO annual meeting in Chicago on June 2, 2018.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal

    Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.

  • Europe's JUPITER supercomputer. Big pharma companies are racing to use AI and supercomputing in drug R&D
    Image attribution tooltip
    Sascha Schuermann/Getty Images via Getty Images
    Image attribution tooltip

    Why Big Pharma is chasing the industry’s most-powerful supercomputer

    Bristol Myers Squibb is the latest major drugmaker to tap Nvidia for more computing power, betting that larger models and AI agents can speed drug discovery.

  • The building features a modern glass façade with the Nasdaq logo prominently displayed. Surrounding the structure are other commercial buildings and digital billboards, which are characteristic of the vibrant Times Square environment.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Pain drugs

    Latigo IPO raises nearly $350M for pain drug development

    The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.

  • A thumbnail illustration for BioPharma Dive's IPO tracker
    Image attribution tooltip
    Adeline Kon/BioPharma Dive
    Image attribution tooltip
    Deep Dive // IPO window

    Biotech IPOs are the industry’s lifeblood. Track how they’re performing.

    Drug startups have banked $6 billion in IPOs so far in 2026, more than the combined amount raised by this point in the previous four years.

    Updated Aug. 7, 2026
  • Close up of eye with retina visible
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Emerging biotech

    Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M

    Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger once called, “if it works, the most perfect drug I’ve ever seen.” 

  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit

    Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Takeda approval ushers in new wave of sleep drugs

    An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that boost “orexin” proteins.

  • The logo of the Food and Drug Administration is seen in a close-up view of the agency's website.
    Image attribution tooltip
    Mario Guti via Getty Images
    Image attribution tooltip

    Replimune rebounds to win FDA approval of melanoma drug

    The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

  • A cooler for an organ transplant sits on a cart in an operating room, as a hospital staffer works behind.
    Image attribution tooltip
    Sean Gallup via Getty Images
    Image attribution tooltip
    Emerging biotech

    With $263M, LifeMine unearths a new drug for organ transplants

    Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs. 

  • Portrait of a brown-haired man smiling at the camera.
    Image attribution tooltip
    Permission granted by HI-Bio
    Image attribution tooltip
    IPO window

    Cardiac drug developer Braveheart banks more than $382M in IPO

    Braveheart’s offering was the largest among four biotech IPOs that collectively raised more than $1 billion from public investors last week.

    Updated Aug. 6, 2026
  • Engraving on a wall reads "wall street."
    Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

    Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

  • A Moderna logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip
    Vaccines

    FDA approves Moderna’s mRNA flu vaccine

    The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory turnaround.

    FDA
  • A picture of CDC director Erica Schwartz testifying at a Senate confirmation hearing.
    Image attribution tooltip
    Finn Gomez / Staff via Getty Images
    Image attribution tooltip
    Vaccines

    Erica Schwartz confirmed as next CDC director

    Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

    FDA
  • An AstraZeneca logo stands atop an office building in Shanghai, China.
    Image attribution tooltip
    Robert Way via Getty Images
    Image attribution tooltip

    An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.

    In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.

  • Glucagon-like peptide 1 (GLP1, 7-36) molecule The glucagon like peptide-1 receptor has a strong effect on the management of type 2 diabetes mellitus.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Lilly climbs, Novo falls as obesity drug battle intensifies

    A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

  • Front view of the NASDAQ MarketSite, which occupies the northwest corner at the base of the 4 Times Square building, in Midtown Manhattan, New York City.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    IPO window

    Attovia adds to biotech IPO momentum with $289M offering

    The startup is the 12th drug company to bank at least $250 million in an IPO this year, nearly matching totals last seen during the sector’s pandemic peak, according to BioPharma Dive data.

  • A 3D illustration of a pair of lungs inside the rib cage.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    A COPD drug from China draws $115M in venture funding

    Expedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.

  • A photo of Vertex Pharmaceuticals' Boston headquarters.
    Image attribution tooltip
    Courtesy of Vertex Pharmaceuticals
    Image attribution tooltip

    Vertex’s biggest overhang: a rival 50 times smaller

    Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics "looms large" over Vertex.

  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip

    Pfizer expands multibillion-dollar cost-cutting plan

    Hatched three years ago, the restructuring is now expected to deliver $1 billion in new cost reductions and save Pfizer another $1.5 billion by streamlining drug production.

  • A stylized illustration of a "patent thicket" for Jonathan Gardner's Nov. 1 story on Amgen's Enbrel.
    Image attribution tooltip
    Adeline Kon / BioPharma Dive/BioPharma Dive
    Image attribution tooltip
    Deep Dive // Patent thickets

    Drug patents protect pharma profits. Track when they’ll expire.

    BioPharma Dive has refreshed its annual list of the expected patent expirations for the world’s best-selling medicines. Many of the top 10 will lose exclusivity this decade.

    Updated Aug. 4, 2026
  • A stack of newspapers are seen against a blue background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    News roundup

    J&J pharma leader to retire; Krystal slumps on gene therapy miss

    Jennifer Taubert will step down after a lengthy run leading J&J’s pharmaceutical business. Elsewhere, pricing issues hampered what Wall Street analysts view as an otherwise strong gene therapy launch.

  • An Alnylam logo is displayed on a building in Cambridge, Massachusetts, on Sept. 5, 2024.
    Image attribution tooltip
    Jacob Bell/BioPharma Dive
    Image attribution tooltip

    Alnylam plunges as earnings deliver ‘one-two punch’

    The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.

  • Sign reads "wall street" with "stock exchange" engraved on a building in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Supernus, Indivior merge to beef up brain drug portfolio

    The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.